Investment in research and development for new and improved treatments is contributing to market growth.

WILMINGTON, Del., Aug. 1, 2024 /PRNewswire/ -- The Non-Hodgkin's lymphoma therapeutics market was projected to attain US$ 8.0 billion in 2023. It is likely to garner an 8.0% CAGR from 2024 to 2034, and by 2034, the market is expected to attain US$ 18.6 billion. Existing treatments may not be effective for all patients, creating a demand for new therapies. There is a shift towards personalized medicine with therapies targeting specific cancer cells or molecular pathways, such as monoclonal antibodies and kinase inhibitors.

The use of immune checkpoint inhibitors and CAR-T cell therapies is becoming more prevalent, offering new hope for NHL patients. Combining different therapeutic approaches (e.g., chemotherapy with targeted therapy) is gaining traction to improve efficacy and reduce resistance. Advances in biomarker identification are enhancing the ability to diagnose NHL early and tailor treatments to individual patients. Increased access to healthcare in emerging markets is expanding the availability of NHL therapies.

Download Sample of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2668

There is potential for significant growth in the market with the development of new drugs and therapies that address unmet needs. Initiatives that support patients through their treatment journey can enhance patient adherence and improve outcomes. Improved awareness and screening programs lead to earlier detection and diagnosis of NHL, increasing the demand for therapeutic options. Better understanding of the genetic basis of NHL enables the development of targeted therapies that are more effective and have fewer side effects.

Non-Hodgkin's Lymphoma Therapeutics Market Report Scope:

Non-Hodgkin's Lymphoma Therapeutics Market: Key Players

The non-hodgkin's lymphoma therapeutics market is characterized by intense competition among pharmaceutical and biotechnology companies, driven by the demand for innovative and effective treatments. The following companies are well known participants in the non-hodgkin's lymphoma therapeutics market:

• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Pfizer Inc.
• GSK plc
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Merck & Co. Inc.
• AbbVie Inc.
• AstraZeneca plc
• Johnson & Johnson Pvt. Ltd.

Key Developments

• In 2021, Kyowa Kirin Co., Ltd., in collaboration with MEI Pharma, Inc., announced the completion of patient enrollment for the Follicular Lymphoma Primary Efficacy Population in their global Phase 2 TIDAL study.
• In the same year, Bristol-Myers Squibb Company announced that the U.S. FDA had approved their CAR-T cell therapy, Breyanzi, for the treatment of large B-cell lymphoma in patients who have relapsed or not responded after at least two other systemic treatments.

Key Findings of the Market Report

• Innovations in imaging and diagnostic technologies, such as PET and MRI scans, facilitate more accurate disease staging and treatment planning.
• The integration of digital health technologies, such as telemedicine and mobile health apps, enhances patient monitoring and management, leading to better outcomes.
• Personalized treatment plans and patient-centric care models are gaining prominence, improving patient experiences and adherence to therapies.
• There is a growing emphasis on managing long-term therapy effects and improving the quality of life for patients through supportive care and symptom management.

Market Trends for Non-Hodgkin's Lymphoma Therapeutics

• By treatment therapy, the imunotherapy segment is expected to boost the growth of the non-hodgkin's lymphoma therapeutics market. Immunotherapy includes advanced treatments such as CAR-T cell therapy, immune checkpoint inhibitors, and monoclonal antibodies, which have shown significant promise in treating various types of NHL. These innovations offer new hope for patients who do not respond well to traditional therapies.
• In terms of indication type, the B-cell lymphomas segment is anticipated to augment the growth of the non-hodgkin's lymphoma therapeutics market. B-cell lymphomas are more common compared to T-cell lymphomas, which translates to a larger patient population and a higher demand for therapeutic options. Significant advancements in treatments for B-cell lymphomas, such as CAR-T cell therapies (e.g., Kymriah and Yescarta) and novel monoclonal antibodies (e.g., Rituximab), have improved patient outcomes and increased market growth. 

Explore Sample of the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2668

Global Market for Non-Hodgkin's Lymphoma Therapeutics: Regional Outlook

North America

• North America has a high incidence and prevalence of NHL, leading to a significant patient population and increased demand for effective therapeutic options.
• The region boasts a well-developed healthcare infrastructure, including state-of-the-art medical facilities, advanced diagnostic tools, and cutting-edge treatment options, which supports the growth of the NHL therapeutics market. 

Asia Pacific

• The introduction and expansion of new treatments, including targeted therapies and immunotherapies, are becoming more accessible in Asia Pacific countries, driving market growth.
• Growing awareness about NHL and improvements in diagnostic capabilities are leading to earlier diagnosis and treatment, boosting the demand for therapeutic solutions.

Non-Hodgkin's Lymphoma Therapeutics Market Segmentation

Treatment Therapy

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others (Radiation Therapy, etc.)

Indication Type

• B-Cell Lymphomas
• T-Cell Lymphomas

Route of Administration

• Oral
• Parenteral

End User

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa 

Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=2668&ltype=S 

More Trending Report by Transparency Market Research:

• Vaccines Market: The global vaccines market is projected to expand at a CAGR of 4.2% during the forecast period from 2023 to 2031
• Laser Capture Microdissection Market: Market for Laser Capture Microdissection is expected to grow at a CAGR of 10.7% from 2024 to 2034 and reach US$ 739.6 Mn by the end of 2034
• Electronic Health Records Market likely to surpass USD 50 Bn by 2031, expanding at a 5% CAGR
• IV Bags Market Predicted to Reach USD 1.5 billion by 2032, Expanding at a CAGR of 5.8%

About Transparency Market Research 

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. 

Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com 
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg 

View original content:https://www.prnewswire.com/news-releases/non-hodgkins-lymphoma-therapeutics-market-to-reach-usd-18-6-billion-by-2034-fuelled-by-new-drugs-and-targeted-therapies--latest-report-by-tmr-302212299.html

SOURCE Transparency Market Research